Technical Analysis for CLRB - Cellectar Biosciences, Inc.

Grade Last Price % Change Price Change
D 4.04 10.85% 0.40
CLRB closed down 5.58 percent on Wednesday, March 27, 2024, on 1.24 times normal volume. The stock fell below its 50 day moving average, damaging its intermediate-term outlook by crossing under that important trendline.
2 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Up Up Up

Date Alert Name Type % Chg
Fell Below 20 DMA Bearish 11.00%
Fell Below 50 DMA Bearish 11.00%
MACD Bearish Signal Line Cross Bearish 11.00%
Earnings Movers Other 11.00%
Down 3 Days in a Row Weakness 11.00%
20 DMA Support Bullish 4.81%
20 DMA Support Bullish -0.37%
MACD Bullish Signal Line Cross Bullish -0.37%
Crossed Above 20 DMA Bullish 4.26%
Gapped Up Strength 4.26%

   Recent Intraday Alerts

Alert Time
Up 10% 11 minutes ago
Possible NR7 38 minutes ago
60 Minute Opening Range Breakout about 2 hours ago
20 DMA Support about 5 hours ago
2x Volume Pace about 5 hours ago

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Cellectar Biosciences, Inc. Description

Cellectar Biosciences, Inc., a development stage biopharmaceutical company, develops compounds for the treatment and imaging of cancer. Its proprietary product candidates include I-124-CLR1404, a small-molecule, broad-spectrum, and cancer-targeting positron emission tomography (PET) imaging agent that is in Phase II clinical trial for glioblastoma, as well as in Phase I/II clinical trials for approximately 11 solid tumor indications; and CLR1502, a preclinical, cancer-targeted, and non-radioactive optical imaging agent for intraoperative tumor margin illumination and non-invasive tumor imaging. The company also develops I-131-CLR1404, a small-molecule, broad-spectrum, and cancer-targeted molecular radiotherapeutic that delivers cytotoxic radiation directly and selectively to cancer cells and cancer stem cells, as well as is in Phase Ib dose-escalation trial for patients with advanced solid tumors; and CLR1404, a cancer-targeted chemotherapy. The company was formerly known as Novelos Therapeutics, Inc. and changed its name to Cellectar Biosciences, Inc. in February 2014. Cellectar Biosciences, Inc. was founded in 2002 and is headquartered in Madison, Wisconsin.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Cancer Clinical Medicine Solid Tumors Imaging Oncology Stem Cell Radiation Chemotherapy Antineoplastic Drugs Occupational Safety And Health Blastoma Glioblastoma Radiation Therapy Targeted Therapy Advanced Solid Tumors Tomography Imaging Agent Positron Emission Tomography Cancer Stem Cell Cancer Stem Cells

Is CLRB a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 4.45
52 Week Low 1.3
Average Volume 1,202,672
200-Day Moving Average 2.62
50-Day Moving Average 3.68
20-Day Moving Average 3.82
10-Day Moving Average 3.70
Average True Range 0.27
RSI (14) 47.64
ADX 29.38
+DI 25.68
-DI 18.78
Chandelier Exit (Long, 3 ATRs) 3.63
Chandelier Exit (Short, 3 ATRs) 4.17
Upper Bollinger Bands 4.32
Lower Bollinger Band 3.32
Percent B (%b) 0.32
BandWidth 26.25
MACD Line 0.04
MACD Signal Line 0.05
MACD Histogram -0.0063
Fundamentals Value
Market Cap 44.67 Million
Num Shares 12.3 Million
EPS -3.26
Price-to-Earnings (P/E) Ratio -1.12
Price-to-Sales 0.00
Price-to-Book 2.67
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 4.16
Resistance 3 (R3) 4.18 4.03 4.07
Resistance 2 (R2) 4.03 3.90 4.02 4.04
Resistance 1 (R1) 3.83 3.82 3.76 3.81 4.01
Pivot Point 3.68 3.68 3.64 3.67 3.68
Support 1 (S1) 3.48 3.55 3.41 3.46 3.26
Support 2 (S2) 3.33 3.47 3.32 3.23
Support 3 (S3) 3.13 3.33 3.20
Support 4 (S4) 3.11